The nephrotoxicity of the anti-manic-depressive drug lithium (Li) is well recognized but the effects of fluctuation in plasma levels from different Li dosage regimens are not. Experiments were done to compare the nephrotoxicity of Li in rats treated either with subcutaneous multiple injections (SMI) or by infusion using mini-osmotic pumps (MOP) vs concurrent controls. A dose of 2 meq/kg/day of LiCl dissolved in saline was given for 8 consecutive days. During treatment, the animals were kept in individual metabolism cages and their plasma Li levels, water intake, urine volume, pH, and osmolality were monitored daily. In the SMI group, average daily plasma Li levels, 30 min post-injection and just prior to the next injection, were 2.6 and 0.34 meq/liter, respectively. The daily mean plasma Li level in the MOP group was 0.39 meq/liter. While both Li treatment groups showed evidence of toxicity not seen in the respective controls, overall differences in the nephrotoxic response between the Li regimens emerged on Days 6 to 8. Thus water consumption and urine volume were both raised with SMI and by Day 8 the urine osmolality was reduced (all p less than 0.05). The results indicate that after administering equivalent amounts of Li, SMI treatment produced a higher degree of nephrotoxicity than the MOP treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0272-0590(92)90122-x | DOI Listing |
Neurol Neuroimmunol Neuroinflamm
March 2025
Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney.
Background And Objectives: Despite the absence of acute lesion activity in multiple sclerosis (MS), chronic neurodegeneration continues to progress, and a potential underlying mechanism could be the kynurenine pathway (KP). Prolonged activation of the KP from chronic inflammation is known to exacerbate the progression of neurodegenerative diseases through the production of neurotoxic metabolites. Among the 8 KP metabolites, six of them, namely kynurenine (KYN), 3-hydroxylkynurenine (3HK), anthranilic acid (AA), kynurenic acid (KYNA), and quinolinic acid (QUIN), have been associated with neurodegeneration.
View Article and Find Full Text PDFPLoS One
January 2025
Department of Laboratory, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, P.R. China.
Background: Systemic lupus erythematosus (SLE) is a complex and incurable autoimmune disease, so several drug remission for SLE symptoms have been developed and used at present. However, treatment varies by patient and disease activity, and existing medications for SLE were far from satisfactory. Novel drug targets to be found for SLE therapy are still needed.
View Article and Find Full Text PDFPLoS One
January 2025
Department of Pain Medicine, Aichi Medical University, Nagakute, Aichi, Japan.
Background: Lowering barometric pressure (LP) can exacerbate neuropathic pain. However, animal studies in this field are limited to a few conditions. Furthermore, although sympathetic involvement has been reported as a possible mechanism, whether the sympathetic nervous system is involved in the hypothalamic-pituitary-adrenal (HPA) axis remains unknown.
View Article and Find Full Text PDFJ Dev Behav Pediatr
January 2025
Department of Pediatrics and Norton Children's Research Institute, School of Medicine, University of Louisville, Louisville, KY.
Objective: Autism spectrum disorder (ASD) is a complex neurodevelopmental condition characterized by social communication differences and restricted interests. One proposed biologic mechanism underlying ASD is oxidative stress, leading to the clinical use of glutathione based on anecdotal reports of improved behavior in autistic children. In this pilot study, we tested this observation using a randomized clinical trial format to collect preliminary data on glutathione safety and efficacy.
View Article and Find Full Text PDFCirc Heart Fail
January 2025
First Faculty of Medicine, Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University (BIOCEV), Charles University, Prague, Czech Republic. (M.B., D.L., O.V., J.P.).
Background: Right ventricular dysfunction (RVD) is common in patients with heart failure with reduced ejection fraction, and it is associated with poor prognosis. However, no biomarker reflecting RVD is available for routine clinical use.
Methods: Proteomic analysis of myocardium from the left ventricle and right ventricle (RV) of patients with heart failure with reduced ejection fraction with (n=10) and without RVD (n=10) who underwent heart transplantation was performed.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!